Study identifier:D1680C00005
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A 24-Week International, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled, Phase III study to Evaluate the Efficacy and Safety of Saxagliptin in Adult Patients with Type 2 Diabetes who have Inadequate Glycaemic Control with Diet and Exercise.
Type 2 Diabetes
Phase 3
No
Saxagliptin, Placebo
All
568
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Aug 2011 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
Bristol-Myers Squibb
Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to evaluate the efficacy and safety in adult patients with inadequate glycaemic control with diet and exercise.
Location
Location
HEFEI, Anhui, China
Location
BEIJING, CHINA, China
Location
CHONGQING, CHINA, China
Location
FUZHOU, Fujian, China
Location
GUANGZHOU, Guangdong, China
Location
Shijiazhuang, Hebei, China
Location
CHANGSHA, Hunan, China
Location
NANJING, Jiangsu, China
Arms | Assigned Interventions |
---|---|
Experimental: Saxagliptin 5mg | Drug: Saxagliptin 5mg, oral tablet, once daily for 24 weeks Other Name: Onglyza |
Placebo Comparator: Placebo | Drug: Placebo oral tablet, once daily for 24 weeks |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.